Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)

Clinical Pharmacokinetics

Volumn 53, Issue 12, 2014, Pages 1115-1136

  Chan, Lingtak Neander ^a   Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALMOTRIPTAN; AMFEBUTAMONE; AMITRIPTYLINE; APREPITANT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIPROFLOXACIN; ERYTHROMYCIN; FELODIPINE; FLUVOXAMINE; GABAPENTIN; IBUPROFEN; METHYLPHENIDATE; MORPHINE; NIFEDIPINE; OXYCODONE; PARACETAMOL; PHENYTOIN; PROCAINAMIDE; RETIGABINE; TETRAHYDROLIPSTATIN; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; WARFARIN; ZOLPIDEM; ALCOHOL DEHYDROGENASE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 2E1 INHIBITOR; GASTROINTESTINAL AGENT;

ALCOHOL METABOLISM; AREA UNDER THE CURVE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; DRUG ABSORPTION; DRUG ACETYLATION; DRUG CLEARANCE; DRUG EFFECT; DRUG INTOXICATION; EUPHORIA; FLUSHING; GASTROINTESTINAL TRACT; HUMAN; HYPOTENSION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; ANTAGONISTS AND INHIBITORS; DRINKING BEHAVIOR; DRUG INTERACTION; METABOLISM;

ALCOHOL DEHYDROGENASE; ALCOHOL DRINKING; ANALGESICS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P-450 CYP2E1 INHIBITORS; DRUG INTERACTIONS; ETHANOL; GASTROINTESTINAL AGENTS; HUMANS;

EID: 84921937523     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0190-x     Document Type: Review

References (198)

1. Substance Abuse & Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health (NSDUH). 2012. http://who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_2.pdf?ua=1. Accessed 25 May 2014.
2. The World Health Organization. Global status report on alcohol and health. 2014. http://who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_2.pdf?ua=1. Accessed 25 May 2014.
3. Centers for Disease Control and Prevention. http://www.cdc.gov/alcohol/data-stats.htm. Accessed 25 May 2014.
4. Norberg A, Jones AW, Hahn RG, et al. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet. 2003;42(1):1–31.
5. Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16(4):667–85.
6. Salaspuro MP, Lindros KO, Pikkarainen PH. Effect of 4-methylpyrazole on ethanol elimination rate and hepatic redox changes in alcoholics with adequate or inadequate nutrition and in nonalcoholic controls. Metabolism. 1978;27(6):631–9.
7. Matsumoto H, Fukui Y. Pharmacokinetics of ethanol: a review of the methodology. Addict Biol. 2002;7(1):5–14.
8. Shankar K, Ronis MJ, Badger TM. Effects of pregnancy and nutritional status on alcohol metabolism. Alcohol Res Health. 2007;30(1):55–9.
9. Riveros-Rosas H, Julian-Sanchez A, Pina E. Enzymology of ethanol and acetaldehyde metabolism in mammals. Arch Med Res. 1997;28(4):453–71.
10. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health. 2007;30(1):5–13.
11. Crabb DW, Matsumoto M, Chang D, et al. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004;63(1):49–63.
12. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997;77(2):517–44.
13. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol. 2004;44:27–42.
14. Aubert J, Begriche K, Knockaert L, et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011;35(10):630–7.
15. Ahn CY, Bae SK, Jung YS, et al. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug Metab Dispos. 2008;36(7):1233–41.
16. Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol. 1998;12(5):553–8.
17. Brown BL, Allis JW, Simmons JE, et al. Fasting for less than 24 h induces cytochrome P450 2E1 and 2B1/2 activities in rats. Toxicol Lett. 1995;81(1):39–44.
18. O’Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 1994;56(4):359–67.
19. McGehee RE Jr, Ronis MJ, Cowherd RM, et al. Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. Biochem Pharmacol. 1994;48(9):1823–33.
20. Koop DR, Tierney DJ. Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. BioEssays 1990;12(9):429–35.
21. Ferreira MP, Weems MK. Alcohol consumption by aging adults in the United States: health benefits and detriments. J Am Diet Assoc. 2008;108(10):1668–76.
22. Seidl S, Wurst FM, Alt A. Ethyl glucuronide-a biological marker for recent alcohol consumption. Addict Biol. 2001;6(3):205–12.
23. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95–9.
24. Baraona E, Abittan CS, Dohmen K, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res. 2001;25(4):502–7.
25. Correa CL, Oga S. Effects of the menstrual cycle of white women on ethanol toxicokinetics. J Stud Alcohol. 2004;65(2):227–31.
26. Lucey MR, Hill EM, Young JP, et al. The influences of age and gender on blood ethanol concentrations in healthy humans. J Stud Alcohol. 1999;60(1):103–10.
27. Cigarroa RG, Lange RA, Popma JJ, et al. Ethanol-induced coronary vasodilation in patients with and without coronary artery disease. Am Heart J. 1990;119(2 Pt 1):254–9.
28. Gazzieri D, Trevisani M, Tarantini F, et al. Ethanol dilates coronary arteries and increases coronary flow via transient receptor potential vanilloid 1 and calcitonin gene-related peptide. Cardiovasc Res. 2006;70(3):589–99.
29. Marchi KC, Muniz JJ, Tirapelli CR. Hypertension and chronic ethanol consumption: what do we know after a century of study? World J Cardiol. 2014;6(5):283–94.
30. Rossinen J, Sinisalo J, Partanen J, et al. Effects of acute alcohol infusion on duration and dispersion of QT interval in male patients with coronary artery disease and in healthy controls. Clin Cardiol. 1999;22(9):591–4.
31. Thomas AP, Rozanski DJ, Renard DC, et al. Effects of ethanol on the contractile function of the heart: a review. Alcohol Clin Exp Res. 1994;18(1):121–31.
32. Greenspon AJ, Schaal SF. The “holiday heart”: electrophysiologic studies of alcohol effects in alcoholics. Ann Intern Med. 1983;98(2):135–9.
33. Sengul C, Cevik C, Ozveren O, et al. Acute alcohol consumption is associated with increased interatrial electromechanical delay in healthy men. Cardiol J. 2011;18(6):682–6.
34. Sano F, Ohira T, Kitamura A, et al. Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). Circ J. 2014;78(4):955–61.
35. Ghahramani P, Ellis SW, Lennard MS, et al. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997;43(2):137–44.
36. Scott DB, Fagan D, Tiplady B. Effects of amitriptyline and zimelidine in combination with ethanol. Psychopharmacology (Berl). 1982;76(3):209–11.
37. Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol. 1984;18(4):549–57.
38. Dorian P, Sellers EM, Reed KL, et al. Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol. 1983;25(3):325–31.
39. Allen D, Lader M. Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol. 1989;4(Suppl 1):7–14.
40. Linnoila M, Johnson J, Dubyoski K, et al. Effects of antidepressants on skilled performance. Br J Clin Pharmacol. 1984;18(Suppl 1):109S–20S.
41. Seppala T, Stromberg C, Bergman I. Effects of zimeldine, mianserin and amitriptyline on psychomotor skills and their interaction with ethanol a placebo controlled cross-over study. Eur J Clin Pharmacol. 1984;27(2):181–9.
42. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000;28(10):1222–30.
43. Posner J, Bye A, Jeal S, et al. Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol. 1984;26(5):627–30.
44. Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica. 2007;37(2):169–79.
45. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73–8.
46. Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther. 1995;58(4):399–403.
47. van Harten J, Stevens LA, Raghoebar M, et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther. 1992;52(4):427–35.
48. Linnoila M, Stapleton JM, George DT, et al. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol. 1993;13(3):175–80.
49. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41(2):149–56.
50. Lindh JD, Annas A, Meurling L, et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol. 2003;59(5–6):401–6.
51. Troy SM, Turner MB, Unruh M, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. J Clin Pharmacol. 1997;37(11):1073–81.
52. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine: role of CYP3A4 and CYP2A8 in 10,11 epoxide formation. Biochem Pharmacol. 1994;47:1969–79.
53. Sternebring B, Liden A, Andersson K, et al. Carbamazepine kinetics and adverse effects during and after ethanol exposure in alcoholics and in healthy volunteers. Eur J Clin Pharmacol. 1992;43(4):393–7.
54. Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol. 2013;8(4):319–31.
55. Crean CS, Tompson DJ. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Clin Ther. 2013;35(1):87–93.
56. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56:154–9.
57. Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend. 2006;83(1):25–32.
58. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolites. Drug Metab Dispos. 1996;24:1401–3.
59. Sandor P, Sellers EM, Dumbrell M, et al. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther. 1981;30(3):390–7.
60. Kater RM, Roggin G, Tobon F, et al. Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci. 1969;258(1):35–9.
61. Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450–mediated metabolism. Clin Pharmacol Ther. 2006;80(3):235–45.
62. Maxwell HG, Dubois S, Weaver B, et al. The additive effects of alcohol and benzodiazepines on driving. Can J Public Health. 2010;101(5):353–7.
63. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician. 1998;44:799–808.
64. Orriols L, Philip P, Moore N, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595–601.
65. Linnoila M. Effects of diazepam, chlordiazepoxide, thioridazine, haloperidole, flupenthixole and alcohol on psychomotor skills related to driving. Ann Med Exp Biol Fenn. 1973;51(3):125–32.
66. Eves FF, Lader MH. The effects of alcohol on psychological functions in normal volunteers after 8 days’ treatment with pipequaline (PK 8165), diazepam or placebo. Eur J Clin Pharmacol. 1989;36(1):47–52.
67. Willumeit HP, Ott H, Neubert W, et al. Alcohol interaction of lormetazepam, mepindolol sulphate and diazepam measured by performance on the driving simulator. Pharmacopsychiatry. 1984;17(2):36–43.
68. Seppala T, Aranko K, Mattila MJ, et al. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther. 1982;32(2):201–7.
69. Willumeit HP, Ott H, Neubert W. Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and long-acting benzodiazepines. Psychopharmacology. 1984;1(Suppl):182–92.
70. Sellers EM, Busto U. Benzodiazepines and ethanol: assessment of the effects and consequences of psychotropic drug interactions. J Clin Psychopharmacol. 1982;2(4):249–62.
71. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994;38:131–7.
72. Sellers EM, Naranjo CA, Giles HG, et al. Intravenous diazepam and oral ethanol interaction. Clin Pharmacol Ther. 1980;28(5):638–45.
73. Hayes SL, Pablo G, Radomski T, et al. Ethanol and oral diazepam absorption. N Engl J Med. 1977;296(4):186–9.
74. Erwin CW, Linnoila M, Hartwell J, et al. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol. 1986;6(4):199–209.
75. van Steveninck AL, Gieschke R, Schoemaker RC, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol. 1996;41(6):565–73.
76. Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32(11):1279–86.
77. Taeuber K, Badian M, Brettel HF, et al. Kinetic and dynamic interaction of clobazam and alcohol. Br J Clin Pharmacol. 1979;7(Suppl 1):91S–7S.
78. Uchaipichat V, Suthisisang C, Miners JO. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos. 2013;41(6):1273–84.
79. Hoyumpa AM, Patwardhan R, Maples M, et al. Effect of short-term ethanol administration on lorazepam clearance. Hepatology. 1981;1(1):47–53.
80. Soo-ampon S, Wongwitdecha N, Plasen S, et al. Effects of word frequency on recall memory following lorazepam, alcohol, and lorazepam alcohol interaction in healthy volunteers. Psychopharmacology (Berl). 2004;176(3–4):420–5.
81. Whiting B, Lawrence JR, Skellern GG, et al. Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide. Br J Clin Pharmacol. 1979;7(1):95–100.
82. Perry PJ, Wilding DC, Fowler RC, et al. Absorption of oral intramuscular chlordiazepoxide by alcoholics. Clin Pharmacol Ther. 1978;23(5):535–41.
83. Sellers EM, Greenblatt DJ, Zilm DH, et al. Decline in chlordiazepoxide plasma levels during fixed-dose therapy of alcohol withdrawal. Br J Clin Pharmacol. 1978;6(4):370–2.
84. Sellman R, Kanto J, Raijola E, et al. Human and animal study on elimination from plasma and metabolism of diazepam after chronic alcohol intake. Acta Pharmacol Toxicol (Copenh). 1975;36(1):33–8.
85. Sellman R, Pekkarinen A, Kangas L, et al. Reduced concentrations of plasma diazepam in chronic alcoholic patients following an oral administration of diazepam. Acta Pharmacol Toxicol (Copenh). 1975;36(1):25–32.
86. Gudin JA, Mogali S, Jones JD, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115–30.
87. Ali NA, Marshall RW, Allen EM, et al. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. Br J Clin Pharmacol. 1985;20(6):631–7.
88. Johnson F, Wagner G, Sun S, et al. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain. 2008;9(4):330–6.
89. Sokolowska M, Sun S, Johnson F, et al. The effect of morphine in combination with ethanol on safety, pharmacodynamics, and pharmacokinetic measures in healthy volunteers [abstract]. J Pain. 2007;8:S39.
90. Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003;31(9):1125–33.
91. Lotsch J, Stockmann A, Kobal G, et al. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther. 1996;60(3):316–25.
92. Bodd E, Drevon CA, Kveseth N, et al. Ethanol inhibition of codeine and morphine metabolism in isolated rat hepatocytes. J Pharmacol Exp Ther. 1986;237(1):260–4.
93. Bodd E, Gadeholt G, Christensson PI, et al. Mechanisms behind the inhibitory effect of ethanol on the conjugation of morphine in rat hepatocytes. J Pharmacol Exp Ther. 1986;239(3):887–90.
94. Hoiseth G, Andersen JM, Morland J. Less glucuronidation of morphine in the presence of ethanol in vivo. Eur J Clin Pharmacol. 2013;69(9):1683–7.
95. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain. 1991;47(1):13–9.
96. Sjogren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand. 1998;42(9):1070–5.
97. Soderberg Lofdal KC, Andersson ML, Gustafsson LL. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs. 2013;73(6):533–43.
98. Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Psychopharmacology (Berl). 2011;218(3):471–81.
99. Girre C, Hirschhorn M, Bertaux L, et al. Enhancement of propoxyphene bioavailability by ethanol. Relation to psychomotor and cognitive function in healthy volunteers. Eur J Clin Pharmacol. 1991;41(2):147–52.
100. Rush CR. Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans. Alcohol Clin Exp Res. 2001;25(1):9–17.
101. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40(10):753–72.
102. Markowitz JS, Logan BK, Diamond F, et al. Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol. 1999;19(4):362–6.
103. Markowitz JS, DeVane CL, Boulton DW, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos. 2000;28(6):620–4.
104. Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007;81(3):346–53.
105. Koehm M, Kauert GF, Toennes SW. Influence of ethanol on the pharmacokinetics of methylphenidate’s metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung. 2010;60(5):238–44.
106. McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237–46.
107. Cabarrocas X, Salva M, Pavesi M, et al. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. Int J Clin Pharmacol Ther. 2006;44(9):443–8.
108. Dorian P, Sellers EM, Kaplan HL, et al. Triazolam and ethanol interaction: kinetic and dynamic consequences. Clin Pharmacol Ther. 1985;37(5):558–62.
109. Ochs HR, Greenblatt DJ, Arendt RM, et al. Pharmacokinetic noninteraction of triazolam and ethanol. J Clin Psychopharmacol. 1984;4(2):106–7.
110. Kuitunen T, Mattila MJ, Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol. 1990;5(Suppl 2):115–30.
111. Wilkinson CJ. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry. 1995;56(7):309–18.
112. Roehrs T, Rosenthal L, Koshorek G, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med. 2001;2(4):323–32.
113. Chaudhuri KR, Maule S, Thomaides T, et al. Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure. J Neurol. 1994;241(3):145–52.
114. Saltiel E, Ellrodt AG, Monk JP, et al. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1988;36(4):387–428.
115. Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med. 1989;12(6):357–62.
116. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet. 1996;30(1):28–51.
117. Qureshi S, Laganiere S, Caille G, et al. Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. Pharm Res. 1992;9(5):683–6.
118. Tracy TS, Korzekwa KR, Gonzalez FJ, et al. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999;47(5):545–52.
119. Perez-Reyes M, White WR, Hicks RE. Interaction between ethanol and calcium channel blockers in humans. Alcohol Clin Exp Res. 1992;16(4):769–75.
120. Bauer LA, Schumock G, Horn J, et al. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. Clin Pharmacol Ther. 1992;52(1):6–10.
121. Reidenberg MM, Drayer DE, Levy M, et al. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975;17(6):722–30.
122. Olsen H, Morland J. Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol. 1982;13(2):203–8.
123. Nelson SD. Anagesics-Antipyretics. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 447–53.
124. Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000;67(3):275–82.
125. Knockaert L, Descatoire V, Vadrot N, et al. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro. 2011;25(2):475–84.
126. Thummel KE, Slattery JT, Nelson SD, et al. Effect of ethanol on hepatotoxicity of acetaminophen in mice and on reactive metabolite formation by mouse and human liver microsomes. Toxicol Appl Pharmacol. 1989;100(3):391–7.
127. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther. 1996;60(3):241–6.
128. Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther. 2000;67(6):591–9.
129. Roine R, Gentry RT, Hernandez-Munoz R, et al. Aspirin increases blood alcohol concentrations in humans after ingestion of ethanol. JAMA. 1990;264(18):2406–8.
130. Truitt EB Jr, Gaynor CR, Mehl DL. Aspirin attenuation of alcohol-induced flushing and intoxication in oriental and occidental subjects. Alcohol Alcohol. 1987;1:595–9.
131. Gentry RT, Baraona E, Amir I, et al. Mechanism of the aspirin-induced rise in blood alcohol levels. Life Sci. 1999;65(23):2505–12.
132. Melander O, Liden A, Melander A. Pharmacokinetic interactions of alcohol and acetylsalicylic acid. Eur J Clin Pharmacol. 1995;48(2):151–3.
133. Kechagias S, Jonsson KA, Jones AW. Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. Br J Clin Pharmacol. 1999;48(5):728–32.
134. Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999;94(11):3189–96.
135. Mustonen H, Kivilaakso E. Effect of luminal ethanol on epithelial resistances and cell volume in isolated necturus gastric mucosa. Dig Dis Sci. 2003;48(10):2037–44.
136. Karazniewicz-Lada M, Luczak M, Glowka F. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica. 2009;39(6):476–85.
137. Barron SE, Perry JR, Ferslew KE. The effect of ibuprofen on ethanol concentration and elimination rate. J Forensic Sci. 1992;37(2):432–5.
138. Hernandez-Munoz R, Caballeria J, Baraona E, et al. Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol. Alcohol Clin Exp Res. 1990;14(6):946–50.
139. Palmer RH, Frank WO, Nambi P, et al. Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol. Am J Gastroenterol. 1991;86(12):1749–55.
140. Gupta AM, Baraona E, Lieber CS. Significant increase of blood alcohol by cimetidine after repetitive drinking of small alcohol doses. Alcohol Clin Exp Res. 1995;19(4):1083–7.
141. DiPadova C, Roine R, Frezza M, et al. Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists. JAMA. 1992;267(1):83–6.
142. −1). Br J Clin Pharmacol. 1996;41(2):129–33.
143. Amir I, Anwar N, Baraona E, et al. Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Life Sci. 1996;58(6):511–8.
144. Weinberg DS, Burnham D, Berlin JA. Effect of histamine-2 receptor antagonists on blood alcohol levels: a meta-analysis. J Gen Intern Med. 1998;13(9):594–9.
145. Brown AS, James OF. Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under ‘real-life’ drinking conditions. Aliment Pharmacol Ther. 1998;12(2):141–5.
146. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32(11):1287–92.
147. te Beek ET, Tatosian D, Majumdar A, et al. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state. J Clin Pharmacol. 2013;53(8):846–56.
148. Zhi J, Massarella JW, Melia AT, et al. The pharmacokinetic-pharmacodynamic (digit symbol substitution test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. Clin Pharmacol Ther. 1994;56(5):530–6.
149. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol. 1998;54(9–10):773–7.
150. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy. 2008;28(9):1084–97.
151. Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy. 2005;25(2):303–7.
152. Lindberg RL, Huupponen RK, Viljanen S, et al. Ethanol and the absorption of oral penicillin in man. Int J Clin Pharmacol Ther Toxicol. 1987;25(10):536–8.
153. Morasso MI, Hip A, Marquez M, et al. Amoxicillin kinetics and ethanol ingestion. Int J Clin Pharmacol Ther Toxicol. 1988;26(9):428–31.
154. Lassman HB, Hubbard JW, Chen BL, et al. Lack of interaction between cefpirome and alcohol. J Antimicrob Chemother. 1992;29(Suppl A):47–50.
155. Kamali F. No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. Eur J Clin Pharmacol. 1994;47(1):71–4.
156. Fuhr U, Wolff T, Harder S, et al. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos. 1990;18(6):1005–10.
157. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989;83(2):688–97.
158. Morasso MI, Chavez J, Gai MN, et al. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics. Int J Clin Pharmacol Ther Toxicol. 1990;28(10):426–9.
159. Weber FH Jr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993;88(4):485–90.
160. Seitz C, Garcia P, Arancibia A. Influence of ethanol ingestion on tetracycline kinetics. Int J Clin Pharmacol Ther. 1995;33(8):462–4.
161. Iselius L, Evans DA. Formal genetics of isoniazid metabolism in man. Clin Pharmacokinet. 1983;8(6):541–4.
162. Polasek TM, Elliot DJ, Somogyi AA, et al. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006;61(5):570–84.
163. Park KS, Sohn DH, Veech RL, et al. Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur J Pharmacol. 1993;248(1):7–14.
164. Dattani RG, Harry F, Hutchings AD, et al. The effects of acute ethanol intake on isoniazid pharmacokinetics. Eur J Clin Pharmacol. 2004;60(9):679–82.
165. McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C] abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother. 1999;43(12):2855–61.
166. McDowell JA, Chittick GE, Stevens CP, et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44(6):1686–90.
167. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287–300.
168. McCance-Katz EF, Gruber VA, Beatty G, et al. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med. 2013;7(4):264–70.
169. Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008;66(4):498–507.
170. Gruber VA, Rainey PM, Lum PJ, et al. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013;12(6):375–7.
171. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos. 1998;26(6):552–61.
172. Benowitz NL, Jones RT. Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther. 1977;22(3):259–68.
173. Belgrave BE, Bird KD, Chesher GB, et al. The effect of cannabidiol, alone and in combination with ethanol, on human performance. Psychopharmacology (Berl). 1979;64(2):243–6.
174. Consroe P, Carlini EA, Zwicker AP, et al. Interaction of cannabidiol and alcohol in humans. Psychopharmacology (Berl). 1979;66(1):45–50.
175. Perez-Reyes M, Hicks RE, Bumberry J, et al. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcohol Clin Exp Res. 1988;12(2):268–76.
176. Lukas SE, Benedikt R, Mendelson JH, et al. Marihuana attenuates the rise in plasma ethanol levels in human subjects. Neuropsychopharmacol. 1992;7(1):77–81.
177. Lukas SE, Orozco S. Ethanol increases plasma Delta(9)-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. Drug Alcohol Depend. 2001;64(2):143–9.
178. Ramaekers JG, Theunissen EL, de Brouwer M, et al. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl). 2011;214(2):391–401.
179. Toennes SW, Schneider K, Kauert GF, et al. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Anal Bioanal Chem. 2011;400(1):145–52.
180. Toennes SW, Schneider K, Wunder C, et al. Influence of ethanol on the pharmacokinetic properties of Delta9-tetrahydrocannabinol in oral fluid. J Anal Toxicol. 2013;37(3):152–8.
181. Langel K, Gjerde H, Favretto D, et al. Comparison of drug concentrations between whole blood and oral fluid. Drug Test Anal. 2014;6(5):461–71.
182. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18(3):185–93.
183. Berghaus G, Guo B. Medicines and driver fitness-findings from a meta-analysis of experimental studies as basic information to pateints, physicians and experts. In: Kloeden C, McLean A, editors. T95: proceedings of the 13th international conference on alcohol, drugs and traffic safety. August 13-August 18, 1995. Adelaide, Australia. Adelaide: NHMRC, Road Accident Unit, University of Adelaide;1995. p. 295–300.
184. Ballard ME, de Wit H. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers. Pharmacol Biochem Behav. 2011;97(4):627–31.
185. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 2010;42(6):1855–65.
186. Chesher GB, Franks HM, Hensley VR, et al. The interaction of ethanol and delta9-tetrahydrocannabinol in man: effects on perceptual, cognitive and motor functions. Med J Aust. 1976;2(5):159–63.
187. Peck R, Biasotti A, Borland P, et al. The effects of marijuana and alcohol on actual driving performance. Alcohol Drugs Driv. 1989;2:134–54.
188. Robbe H. Marijuana’s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Hum Psychopharmacol Clin Exp. 1998;13(Suppl 2):S70–8.
189. Brzezinski MR, Abraham TL, Stone CL, et al. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol. 1994;48(9):1747–55.
190. Farre M, de la Torre R, Gonzalez ML, et al. Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther. 1997;283(1):164–76.
191. Mendelson J, Jones RT, Upton R, et al. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther. 1995;57(5):559–68.
192. Hernandez-Lopez C, Farre M, Roset PN, et al. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther. 2002;300(1):236–44.
193. Ku HY, Ahn HJ, Seo KA, et al. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008;36(6):986–90.
194. Wensing G, Bauer R, Unger S, et al. Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in healthy male subjects. Int J Clin Pharmacol Ther. 2006;44(5):216–24.
195. Jacobsen D, Sebastian CS, Dies DF, et al. Kinetic interactions between 4-methylpyrazole and ethanol in healthy humans. Alcohol Clin Exp Res. 1996;20(5):804–9.
196. Madan A, Parkinson A, Faiman MD. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N, N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram. Drug Metab Dispos. 1995;23(10):1153–62.
197. Johansson B, Angelo HR, Christensen JK, Møller IW, Rønsted P. Dose-effect relationship of disulfiram in human volunteers. II: a study of the relation between the disulfiram-alcohol reaction and plasma concentrations of acetaldehyde, diethyldithiocarbamic acid methyl ester, and erythrocyte aldehyde dehydrogenase activity. Pharmacol Toxicol. 1991;68(3):166–70.
198. Wicht F, Fisch HU, Nelles J, et al. Divergence of ethanol and acetaldehyde kinetics and of the disulfiram-alcohol reaction between subjects with and without alcoholic liver disease. Alcohol Clin Exp Res. 1995;19(2):356–61.